Morgan Stanley Gt Biopharma, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.22 - $0.28 $1,777 - $2,261	8,078 New	8,078 $2,000
Q1 2023 May 15, 2023	BUY	$0.46 - $1.05 $122 - $280	267 Added 3.42%	8,078 $4,000
Q4 2022 Feb 14, 2023	BUY	$0.89 - $58.2 $3,778 - $247,117	4,246 Added 119.1%	7,811 $6,000
Q3 2022 Nov 14, 2022	SELL	$1.81 - $56.1 $236,165 - $7.32 Million	-130,478 Reduced 97.34%	3,565 $5,000
Q2 2022 Oct 27, 2022	SELL	$1.64 - $3.11 $217,908 - $413,228	-132,871 Reduced 49.78%	134,043 $400,000
Q2 2022 Aug 15, 2022	SELL	$1.64 - $3.11 $217,908 - $413,228	-132,871 Reduced 49.78%	134,043 $400,000
Q1 2022 Oct 27, 2022	BUY	$2.6 - $3.3 $345,464 - $438,474	132,871 Added 99.13%	266,914 $768,000
Q1 2022 May 13, 2022	SELL	$2.6 - $3.3 $457,288 - $580,404	-175,880 Reduced 39.72%	266,914 $768,000
Q4 2021 Feb 14, 2022	BUY	$3.05 - $7.08 $581,034 - $1.35 Million	190,503 Added 75.51%	442,794 $1.35 Million
Q3 2021 Nov 15, 2021	BUY	$6.68 - $15.26 $1.69 Million - $3.85 Million	252,291 New	252,291 $1.7 Million

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $96.4M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.